Ariad Pharmaceuticals Inc fka ARIA

[LUMA14]

522 Impairment of Longitudinal Growth By Tyrosine Kinase Inhibitor (TKI) Treatment - Data from a Large Pediatric Cohort with Chronic Myeloid Leukemia (CML)

link to abstract

A decade after being licensed for treatment of CML in minors, the TKI imatinib (IMA) is well known for it's inhibitory “off-target” effects on activity and proliferative capacity of osteoclasts and osteoblasts resulting in impaired bone remodeling (Vandyke K et al 2010 Blood 115:766; Tauer JT et al Blood 2011:118).
...
Discussion:
Growth retardation is a significant adverse effect of IMA in children with CML affecting predominantly prepubertal children. Possible medical interventions still need to be investigated.
...

A decade ay “off-target” effects on activity and proliferative capacity of osteoclasts and osteoblasts resulting in impaired bone remodeling (Vandyke K et al 2010 Blood 115:766; Tauer JT et al Blood 2011:118).

Side effects will always happen. No TKI is without them.